24/7 Customer Support
The Global Soft Tissue Sarcoma (STS) Market has been estimated to grow with a CAGR of 7.4% During the Forecast year and was holding a revenue of US$ 3,595.41 Mn in 2022 and is projected to reach US$ 6,465.70 Mn by 2030.
Soft-tissue sarcomas are a rare and diverse category of tumors that develop in the connective tissues of animal cells. The tumors are commonly found in connective tissues such as nerves, tendons, muscles, blood vessels, and fibrous tissues, with a higher prevalence in the hands and legs.
Soft-tissue sarcomas can be classified based on the nature of the malignancy of the tumor, the type of cell, and the clinical source of the disease. The signs and symptoms of STS vary significantly depending on the type of tumor. However, an individual affected by STS may experience a steadily growing painless mass in the affected area. The diagnosis rate of soft tissue sarcoma is increasing, which is expected to drive the growth of the market. According to the American Society of Clinical Oncology (ASCO), approximately 13,130 people in the US are projected to be diagnosed with STS in 2020.
Advancements in the field of medical technology increased awareness about the disease, and the availability of effective treatment options are also expected to contribute to the growth of the STS market. Furthermore, the growing aging population and changing lifestyles that increase the risk of developing soft tissue sarcomas are likely to boost the demand for the diagnosis and treatment of this disease in the coming years.
To Get more Insights, Request A Free Sample
The STS market presents significant opportunities for growth, and this report provides a comprehensive analysis of market opportunities across 7 major countries, namely the U.S., UK, France, Germany, Spain, Italy, and Japan. The patient population has been thoroughly analyzed across these regions based on age, gender, sarcoma type, and stage.
Among these regions, the United States has the highest incidence of STS cases, with 13,608 cases expected in 2022. In the EU5 countries, Germany has the highest incident population of 6,878 for STS in 2022, while Spain has 2,187 cases of STS in the base year. The analysis indicates that there is a gender difference in the disease, with more male cases than female cases observed across all regions. For instance, in the US, over 50% of the male population is expected to be affected by the disease in 2022, while only 43% of the female population is impacted.
The report provides valuable insights into the STS market, which can help stakeholders identify growth opportunities and develop effective strategies to capitalize on them. The analysis of patient population based on age, gender, sarcoma type, and stage can be particularly useful for healthcare providers, policymakers, and other stakeholders in developing targeted interventions to address the disease burden.
According to the American Cancer Society, the estimated incidence of soft tissue sarcoma in 2023 is around 13,400 new cases, with 7,400 in males and 6,000 in females. Additionally, it is estimated that around 5,000 people are likely to die due to soft tissue sarcomas in the same year. The high incidence of the disease is associated with the growing patient population, which ultimately increases the demand for related therapeutics, providing a background for market growth.
Delayed diagnosis and advanced disease or metastasis stage are major reasons for the lethality of soft tissue sarcomas. Around 60% of sarcomas are observed as localized sarcoma, 18% of them are found in a locally advanced stage, and about 15% are diagnosed in the metastatic stage.
The majority of players in the soft tissue sarcoma market are aiming to develop novel drugs and therapies for the treatment of advanced cases of soft tissue sarcoma. Hence, the market witnesses a strong pipeline from the key players and the start-ups. These clinical research paves a way for better treatment and forms the basis of market growth.
Moreover, favorable reimbursement policies are a major consideration for growth in the STS market. Drugs like Yondelis and Halaven are reimbursable. For example, Yondelis is identified with a permanent, drug-specific HCPCS code J9352 and was registered on National Health Insurance (NHI) reimbursement price list in Japan in 2015, with a reimbursement price of approximately USD 459.73 for 0.25mg and USD 1843.31 for 1mg of the drug. This increases the patient’s buying capacity by enabling them to pay out-of-pocket expenses.
One of the major challenges in the market includes the high prices of STS therapies due to the cost of research and development, the cost of developing equipment, cost of radiation therapy and surgery, and the insurance cost. For instance, the treatment cost of third line and second line of treatment of STS is estimated to be over USD 20,000 and USD 10,000. This poses a threat to the adoption of treatments available in the market, thus creating a hindrance to market growth in the future.
Additionally, few of the commercial drugs show adverse events in STS treatment. For instance, Eli Lilly published in 2019 that Lartruvo causes fetal harm when administered by a pregnant woman, and the company withdrew the drug from the market. This consequently increases the patient’s reluctance in opting for treatment, obstructing market growth.
targeted therapy is gaining ground in the soft tissue sarcoma market as it offers a more personalized and effective approach to treatment compared to traditional chemotherapy. Targeted therapy involves using drugs that specifically target the molecular or genetic alterations that are driving the growth and spread of cancer cells.
In soft tissue sarcoma, several targeted therapies have been approved by regulatory bodies such as the US FDA and the European Medicines Agency (EMA). For example, trabectedin, a targeted therapy that works by interfering with DNA repair mechanisms in cancer cells, has been approved for the treatment of liposarcoma and leiomyosarcoma. Another example is imatinib, a targeted therapy that inhibits the activity of the protein that drives gastrointestinal stromal tumors (GISTs), a type of soft tissue sarcoma.
Targeted therapies are becoming increasingly popular because they have shown to be effective in clinical trials, with some studies showing improved survival rates and quality of life for patients. They also have a lower risk of side effects compared to traditional chemotherapy, which can cause damage to healthy cells in addition to cancer cells.
However, targeted therapies are not without their challenges. One major challenge is the development of drug resistance, where cancer cells evolve mechanisms to evade the effects of the drug. This can lead to treatment failure and disease progression. Another challenge is the high cost of targeted therapies, which can limit access for some patients.
Despite these challenges, targeted therapy is expected to continue to gain ground in the soft tissue sarcoma market as more drugs are developed and approved, and as researchers continue to explore ways to overcome resistance and improve treatment outcomes.
North America is the largest region in the global soft tissue sarcoma market, accounting for a significant share of the market revenue. The region's growth is attributed to factors such as the high prevalence of soft tissue sarcoma, the availability of advanced healthcare infrastructure, favorable reimbursement policies, and the presence of major market players.
According to the American Cancer Society, around 13,000 new cases of soft tissue sarcoma are diagnosed in the United States each year. The rising incidence of the disease is mainly due to factors such as aging population and lifestyle changes. Moreover, the availability of advanced diagnostic technologies, such as MRI and CT scans, has also contributed to the early diagnosis of soft tissue sarcoma in North America.
The region's advanced healthcare infrastructure is another major factor contributing to the growth of the soft tissue sarcoma market in North America. The availability of advanced healthcare facilities, such as well-equipped hospitals and specialized cancer treatment centers, has boosted the demand for advanced soft tissue sarcoma treatments. Additionally, the region's favorable reimbursement policies for cancer treatments have also played a significant role in driving the market growth.
Furthermore, the presence of major market players, such as Pfizer Inc., Eli Lilly and Company, and Johnson & Johnson, in North America has led to the development of advanced soft tissue sarcoma treatments. These companies are continuously investing in research and development activities to introduce innovative and effective treatments for soft tissue sarcoma.
However, despite the region's high market share, the market growth in North America is expected to slow down due to the saturation of the market and the availability of alternative treatment options. Nevertheless, the region's established healthcare infrastructure and technological advancements are likely to maintain its position as the leading market in the global soft tissue sarcoma market.
The Global Soft tissue sarcoma (STS) market is sub-segmented into:
LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.SPEAK TO AN ANALYST